BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by BMO Capital Markets

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by research analysts at BMO Capital Markets to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other research analysts have also commented on BMRN. HC Wainwright cut their target price on BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday. Oppenheimer boosted their price target on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Canaccord Genuity Group increased their price objective on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Bank of America reduced their price objective on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

BioMarin Pharmaceutical Trading Up 3.5%

Shares of BMRN opened at $69.33 on Tuesday. The stock’s 50-day moving average price is $60.21 and its 200 day moving average price is $57.74. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $13.42 billion, a price-to-earnings ratio of 187.38, a P/E/G ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. During the same quarter last year, the company earned $1.44 EPS. The company’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, research analysts predict that BioMarin Pharmaceutical will post 4.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BMRN. CIBC Private Wealth Group LLC boosted its stake in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its position in shares of BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after purchasing an additional 183 shares in the last quarter. Caerus Investment Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 2.8% during the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 278 shares in the last quarter. Chicago Partners Investment Group LLC lifted its holdings in BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 290 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BMO upgraded BioMarin to “strong buy.” The firm’s more bullish stance follows its initiation of coverage with an “outperform” rating and a $98 price target, implying substantial upside from the stock’s recent level. Ticker Report article
• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront and up to $215 million in milestone payments. The deal adds ALE1, an oral, clinical-stage treatment for hypophosphatasia (HPP), a rare genetic bone disorder. If successful, ALE1 could broaden BioMarin’s rare-disease portfolio and address a significant unmet need. CNBC article
• Positive Sentiment: Analysts including Barclays, Piper Sandler and Wedbush have highlighted potential for price appreciation or improved long-term growth from the Alesta transaction, reinforcing optimism around BioMarin’s development pipeline. Yahoo Finance article
• Neutral Sentiment: The acquisition carries clinical and regulatory risk. ALE1 remains in early-stage trials, meaning BioMarin must still demonstrate efficacy and safety before the program can generate revenue. The milestone-based structure limits some upfront exposure but could increase the eventual cost if development succeeds. Inside Monkey article
• Negative Sentiment: HC Wainwright remains cautious, maintaining a “neutral” rating and lowering its price target to $59. The target cut highlights valuation concerns and downside risk despite the strategic appeal of the Alesta deal. Benzinga article

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.